IDXX

SEC source: 0001567619-22-020466 · doc1.xml · nonDerivative · entry 3

MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,947.6426

F2 · price: Represents the weighted average price of the shares sold ranging from a low of $433.69 to a high of $434.685 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-22-020466 · doc1.xml · nonDerivative · entry 2

MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,332.6426

F1 · price: Represents the weighted average price of the shares sold ranging from a low of $432.67 to a high of $433.65 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-22-020466 · doc1.xml · nonDerivative · entry 1

MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,304.6426

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-22-020130 · doc1.xml · derivative · entry 11

Turner Kathy V · CIK 0001740719 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,581

Underlying: Common Stock · 8,567 shares

Expires 2028-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · price: Not applicable.

F9 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that vest in five annual installments beginning February 14, 2019.

SEC source: 0001567619-22-020130 · doc1.xml · nonDerivative · entry 8

Turner Kathy V · CIK 0001740719 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,923.3869

F6 · price: Represents the weighted average price of the shares sold ranging from a low of $435.00 to a high of $435.21 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-22-020130 · doc1.xml · nonDerivative · entry 7

Turner Kathy V · CIK 0001740719 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,923.3869

SEC source: 0001567619-22-020130 · doc1.xml · nonDerivative · entry 6

Turner Kathy V · CIK 0001740719 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,293.3869

F5 · price: Represents the weighted average price of the shares sold ranging from a low of $442.00 to a high of $442.0125 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-22-020130 · doc1.xml · nonDerivative · entry 5

Turner Kathy V · CIK 0001740719 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,490.3869

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-22-020130 · doc1.xml · derivative · entry 10

Turner Kathy V · CIK 0001740719 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,056

Underlying: Common Stock · 5,310 shares

Expires 2029-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · price: Not applicable.

F8 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that vest in five annual installments beginning February 14, 2020.

SEC source: 0001567619-22-020130 · doc1.xml · nonDerivative · entry 4

Turner Kathy V · CIK 0001740719 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,923.3869

F4 · price: Represents the weighted average price of the shares sold ranging from a low of $405.00 to a high of $405.87 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-22-020130 · doc1.xml · nonDerivative · entry 3

Turner Kathy V · CIK 0001740719 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,553.3869

F3 · price: Represents the weighted average price of the shares sold ranging from a low of $406.10 to a high of $406.115 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-22-020130 · doc1.xml · nonDerivative · entry 2

Turner Kathy V · CIK 0001740719 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,578.3869

F2 · price: Represents the weighted average price of the shares sold ranging from a low of $410.00 to a high of $410.35 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-22-020130 · doc1.xml · nonDerivative · entry 1

Turner Kathy V · CIK 0001740719 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,233.3869

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes a total of 37 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 31, 2022, June 30, 2022 and, September 30, 2022.

SEC source: 0001567619-22-021350 · doc1.xml · nonDerivative · entry 1

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 170,420

SEC source: 0001567619-22-019388 · doc1.xml · derivative · entry 9

MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 24,002 shares

Expires 2023-12-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · price: Not applicable.

F9 · derivative.exercise_date: Grant of option to buy 24,501 shares of Issuer common stock that became exercisable in five annual installments beginning December 5, 2014 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-22-019388 · doc1.xml · nonDerivative · entry 8

MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,306.6426

F8 · price: Represents the weighted average price of the shares sold ranging from a low of $384.98 to a high of $385.16 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-22-019388 · doc1.xml · nonDerivative · entry 7

MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,698.6426

F7 · price: Represents the weighted average price of the shares sold ranging from a low of $383.97 to a high of $384.935 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-22-019388 · doc1.xml · nonDerivative · entry 6

MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,716.6426

F6 · price: Represents the weighted average price of the shares sold ranging from a low of $382.95 to a high of $383.95 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-22-019388 · doc1.xml · nonDerivative · entry 5

MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,432.6426

F5 · price: Represents the weighted average price of the shares sold ranging from a low of $381.94 to a high of $382.94 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-22-019388 · doc1.xml · nonDerivative · entry 4

MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,136.6426

F4 · price: Represents the weighted average price of the shares sold ranging from a low of $380.68 to a high of $381.04 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-22-019388 · doc1.xml · nonDerivative · entry 3

MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,636.6426

F3 · price: Represents the weighted average price of the shares sold ranging from a low of $379.10 to a high of $380.06 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-22-019388 · doc1.xml · nonDerivative · entry 2

MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,636.6426

F2 · price: Represents the weighted average price of the shares sold ranging from a low of $377.99 to a high of $378.95 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-22-019388 · doc1.xml · nonDerivative · entry 1

MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,536.6426

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 17 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2022

SEC source: 0001567619-22-019020 · doc1.xml · nonDerivative · entry 1

JUNIUS DANIEL M · CIK 0001094159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,968

F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($6,562.50) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock as soon as practicable following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.

SEC source: 0001567619-22-017181 · doc1.xml · nonDerivative · entry 3

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Jonathan W. Ayers 2022 GRAT

Disclosed balance after: 450,000

F1 · balance_after: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2022 GRAT (the "GRAT"). The GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001567619-22-017181 · doc1.xml · nonDerivative · entry 2

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 175,420

SEC source: 0001567619-22-017058 · doc1.xml · derivative · entry 3

Smith Martin Alexander · CIK 0001621358 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,241

Underlying: Common Stock · 19 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning September 1, 2022.

F3 · price: Not applicable.

F2 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning September 1, 2022.

F2 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning September 1, 2022.

SEC source: 0001567619-22-017058 · doc1.xml · nonDerivative · entry 2

Smith Martin Alexander · CIK 0001621358 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43

SEC source: 0001567619-22-017058 · doc1.xml · nonDerivative · entry 1

Smith Martin Alexander · CIK 0001621358 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes a total of 20 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 31, 2022 and June 30, 2022.

SEC source: 0001567619-22-015174 · doc1.xml · derivative · entry 4

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,593

Underlying: Common Stock · 192 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020.

F3 · price: Not applicable.

F2 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020.

F2 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020.

SEC source: 0001567619-22-015174 · doc1.xml · nonDerivative · entry 2

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,275.6426

SEC source: 0001567619-22-015174 · doc1.xml · nonDerivative · entry 1

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,365.6426

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes a total of 20 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 31, 2022 and June 30, 2022.

SEC source: 0001567619-22-015173 · doc1.xml · derivative · entry 3

MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,990

Underlying: Common Stock · 385 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020.

F3 · price: Not applicable.

F2 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020.

F2 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020.

SEC source: 0001567619-22-015173 · doc1.xml · nonDerivative · entry 2

MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,517.6426

SEC source: 0001567619-22-015173 · doc1.xml · nonDerivative · entry 1

MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,696.6426

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 11 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on June 30, 2022.

SEC source: 0001567619-22-017181 · doc1.xml · nonDerivative · entry 1

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 625,420

SEC source: 0001567619-22-014808 · doc1.xml · nonDerivative · entry 1

JUNIUS DANIEL M · CIK 0001094159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,950

F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($6,562.50) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock as soon as practicable following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.

SEC source: 0001567619-22-012326 · doc1.xml · derivative · entry 1

Johnson Michael Perkins · CIK 0001917747 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,382

Underlying: Common Stock · 3,382 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock and vests in one installment on June 1, 2025.

F2 · price: Not applicable.

F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock and vests in one installment on June 1, 2025.

F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock and vests in one installment on June 1, 2025.

SEC source: 0001567619-22-011529 · doc1.xml · derivative · entry 2

MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 706 shares

Expires 2027-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy 706 shares of IDEXX Laboratories, Inc. common stock that vested in one installment on February 14, 2022.

SEC source: 0001567619-22-011529 · doc1.xml · nonDerivative · entry 1

MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,300.6426

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 9 shares purchased under the Issuer's Employee Stock Purchase Plan on March 31, 2022.

SEC source: 0001567619-22-010582 · doc1.xml · derivative · entry 2

SAMAD SAM · CIK 0001694295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 945

Underlying: Common Stock · 945 shares

Expires 2032-05-10

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-22-010582 · doc1.xml · derivative · entry 1

SAMAD SAM · CIK 0001694295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 344

Underlying: Common Stock · 344 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.

F3 · price: Not applicable.

F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.

F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.

SEC source: 0001567619-22-010581 · doc1.xml · derivative · entry 2

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 945

Underlying: Common Stock · 945 shares

Expires 2032-05-10

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-22-010581 · doc1.xml · derivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 344

Underlying: Common Stock · 344 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.

F3 · price: Not applicable.

F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.

F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.

SEC source: 0001567619-22-010580 · doc1.xml · derivative · entry 5

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 344

Underlying: Common Stock · 224 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event was earlier.

F4 · price: Not applicable.

F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event was earlier.

F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event was earlier.

SEC source: 0001567619-22-010580 · doc1.xml · derivative · entry 4

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 568

Underlying: Common Stock · 344 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier.

F4 · price: Not applicable.

F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier.

F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-22-010580 · doc1.xml · derivative · entry 3

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 945

Underlying: Common Stock · 945 shares

Expires 2032-05-10

F4 · price: Not applicable.

F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-22-010580 · doc1.xml · nonDerivative · entry 1

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 872

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-22-010579 · doc1.xml · derivative · entry 6

SZOSTAK M ANNE · CIK 0001094176 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 344

Underlying: Common Stock · 224 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event was earlier.

F6 · price: Not applicable.

F5 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event was earlier.

F5 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event was earlier.

SEC source: 0001567619-22-010579 · doc1.xml · derivative · entry 5

SZOSTAK M ANNE · CIK 0001094176 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 568

Underlying: Common Stock · 344 shares

Expires not disclosed

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier.

F6 · price: Not applicable.

F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier.

F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier.